Cover Image
市場調查報告書

冠狀動脈疾病(CAD)(缺血性心臟疾病) - 開發中產品分析

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 245962
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
冠狀動脈疾病(CAD)(缺血性心臟疾病) - 開發中產品分析 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
出版日期: 2014年02月28日 內容資訊: 英文 141 Pages
簡介

冠狀動脈疾病(CAD)是由於膽固醇等造成輸送血液到心肌的動脈內壁肥厚硬化造成,最後可能引發胸部疼痛(心絞痛),心臟病發作等。

本報告提供冠狀動脈疾病(CAD)(缺血性心臟疾病)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

冠狀動脈疾病(CAD)(缺血性心臟疾病)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/實驗室別

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • MedImmune, LLC
  • Isis Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Merck & Co., Inc.
  • CardioVascular BioTherapeutics, Inc.
  • Bayer AG
  • AnGes MG, Inc.
  • Pluristem Therapeutics Inc.
  • AngioDesign
  • ViroMed Co., Ltd.
  • Miltenyi Biotec GmbH
  • Multi Gene Vascular Systems Ltd
  • Lonestar Heart, Inc.
  • Biscayne Pharmaceuticals, Inc.

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • cangrelor
  • prasugrel hydrochloride
  • anacetrapib
  • rivaroxaban
  • ranolazine ER
  • CD133+ Autologous Bone Marrow Stem Cells
  • tetrahydrobiopterin + folic acid
  • CVBT-141H
  • CVBT-141A
  • BQ-123
  • ISIS-CRPRx
  • VM-202
  • CD 133 Cells
  • XL-652
  • VM-202
  • beperminogene perplasmid
  • ISIS-APOARx
  • ACP-501
  • GS-6615
  • ACP-01
  • PLX Cells for Peripheral Artery Disease
  • GLP-1
  • MultiGeneGraft
  • BAY-606583
  • Growth Hormone-Releasing Hormone Agonists
  • Drug For Ischemic Heart Disease
  • Anti-CD20 Monoclonal Antibody
  • Angiotensin Converting Enzyme Inhibitors for Cardiovascular Diseases
  • cangrelor - Drug Profile

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 熱門資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4596IDB

Global Markets Direct's, 'Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014', provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview
    • Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • MedImmune, LLC
    • Isis Pharmaceuticals, Inc.
    • Gilead Sciences, Inc.
    • Daiichi Sankyo Company, Limited
    • Merck & Co., Inc.
    • CardioVascular BioTherapeutics, Inc.
    • Bayer AG
    • AnGes MG, Inc.
    • Pluristem Therapeutics Inc.
    • AngioDesign
    • ViroMed Co., Ltd.
    • Miltenyi Biotec GmbH
    • Multi Gene Vascular Systems Ltd
    • Lonestar Heart, Inc.
    • Biscayne Pharmaceuticals, Inc.
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cangrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prasugrel hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anacetrapib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranolazine ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CD133+ Autologous Bone Marrow Stem Cells - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tetrahydrobiopterin + [folic acid] - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVBT-141H - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVBT-141A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BQ-123 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-CRPRx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CD 133 Cells - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XL-652 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-APOARx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACP-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-6615 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX Cells for Peripheral Artery Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLP-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MultiGeneGraft - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-606583 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Growth Hormone-Releasing Hormone Agonists - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug For Ischemic Heart Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Anti-CD20 Monoclonal Antibody - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Angiotensin Converting Enzyme Inhibitors for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cangrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 02, 2014: Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist
      • Sep 03, 2013: Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis
      • Jul 12, 2013: Daiichi Sankyo Announces Phase 3 Study Results for the Antiplatelet Agent Prasugrel in Japan
      • Jul 01, 2013: FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor
      • Apr 11, 2013: Amarantus Announces Preclinical Development Timeline For MANF Therapeutic
      • Apr 08, 2013: Resverlogix To Spin-out Innovative Drug R&D subsidiary RVX Therapeutics
      • Apr 01, 2013: Isis Pharma Publishes Data Demonstrating Antisense Targeting Of ApoC-III Significantly Reduces ApoC-III And Triglycerides
      • Mar 13, 2013: Isis Pharma Reports Clinical Data Showing Blunting Of Severe Increases In CRP Following Endotoxin Challenge With ISIS-CRP Rx
      • Mar 08, 2013: Janssen Launches EXPLORER Global Cardiovascular Research Program For Xarelto
      • Nov 13, 2012: Bayer Announces Initiation Of COMPASS Phase III Study Of Xarelto For Secondary Prevention Of Myocardial Infarction And Death In Patients With Coronary Or Peripheral Artery Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2014
  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca PLC, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AngioDesign, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Assessment by Combination Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2014
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2014
  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Assessment by Combination Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top